The ROC 'n' role of the multiplex assay for early detection of ovarian cancer

Publisher Website
Google Scholar
Abstract
In order to overcome the significant mortality associated with ovarian cancer, a highly sensitive and specific screening test is urgently needed. CA125 is used to assess response to chemotherapy, detect recurrence, and distinguish malignant from benign disease; however, this marker is elevated in only 50–60% of stage I ovarian cancers, making it inadequate for early detection of malignancy. In this Practice Point, we discuss Visintin et al.'s attempt to validate a novel multiplex assay that uses a panel of six serum biomarkers–leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA125. The study included 362 healthy controls and 156 patients with newly diagnosed ovarian cancer. The final model yielded 95.3% sensitivity, 99.4% specificity, a positive predictive value of 99.3% and a negative predictive value of 99.2%. These results indicate potential utility of this assay for early detection of ovarian cancer, although further validation is needed in a sample set representative of the general population.

This publication has 8 references indexed in Scilit: